Timber Pharmaceuticals — Investor Presentation (May 2020)
27 slides from Timber Pharmaceuticals's investor presentation, May 22, 2020
Slide 1: Safe Harbor Statement
Safe Harbor Statement Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitute “forward-looking sta
Slide 2: Introducing Timber Pharmaceuticals, Inc.
3 Introducing Timber Pharmaceuticals, Inc. Timber Pharmaceuticals is building an orphan dermatology company that focuses on mitigating the cost, risk, and time of drug development by leveraging the Orphan Drug pathway for conditions with no FDA Approved treatments. The company’s investigational ther
Slide 3: Investment Highlights
4 Investment Highlights Timber is positioned to become a leading Dermatology company with a focus on orphan diseases, led by a management team with a proven track record in development and commercialization High potential, late stage, low risk multi-product candidate pipeline Proven clinical Proof o
Slide 4: Leadership Team
Leadership Team Strong Balance between Entrepreneurial Acumen and Proven Operational Leadership Michael Derby, MS, MBA, Executive Chairman • • • Pharma entrepreneur with several successful exits Managing Partner of TardiMed Sciences Founder of Norphan Pharmaceuticals, rare neurology drug development
Slide 5: Zach Rome, Chief Operating Officer; Joseph Lucchese, CFO
Zach Rome, Chief Operating Officer Joseph Lucchese, CFO • • Dermatology inventor and entrepreneur Co-founder and President at Patagonia Pharmaceuticals, >$11 million in funding from founders and strategic partner Advanced lead development candidate from concept to Phase 2B clinical studies and was t
Slide 6: World Class Clinical Advisors and Partners
World Class Clinical Clinical Advisors Advisors and Partners Partners • Peter Elias, MD – Professor, Dept of Dermatology, University of California, San Francisco (UCSF) Keith Choate, MD, PhD – Professor of Dermatology, Pathology, and Genetics, Yale University Joyce Teng, MD – Professor and Director
Slide 7: Timber Business Model
• Timber’s strategy focuses on attempting to mitigate the cost, risk, and time of drug development while retaining earnings potential Timber Business Model • Identify compounds with broad and proven mechanisms across many dermatologic conditions. Differentiate the drug product and create a barrier t
Slide 8: Strategically Building Pipeline in Rare Dermatologic Disease
Strategically Building Pipeline in Rare Dermatologic Disease 9 NYSE American: TMBR
Slide 9: Life Cycle Management
Life Cycle Management All products have potential follow-on indications in significant dermatology markets Scars 10 NYSE American: TMBR Sebaceous Hyperplasia Hypertrophic/Keloid Port Wine Stains Severe Acne Scarring Alopecia Darier ’s Disease Sturge-Weber Syndrome TMB-003 TMB-002 TMB-001
Slide 10: Barriers to Entry
Barriers Entry to • • • Orphan exclusivity – 7 years in U.S., 10 years in E.U. Patents pending globally Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxidation, temperature sensitivities, stability challenges, etc. dosing, and other methods of •
Slide 11: TMB-001 for Congenital Ichthyosis
TMB-001for Congenital Ichthyosis A rare disorder of keratinization affecting ~ 80,000 people in the U.S. (>1.5 million globally) Prevalence • X-Linked Ichthyosis has a prevalence of 1:2,000-1:6,000 males • Lamellar Ichthyosis has a prevalence of 1:100,000-200,000 Quality of life is significantly aff
Slide 12: TMB-001 Topical Isotretinoin in CI
TMB-001Topical Isotretinoin in CI Proprietary topical formulation minimizing systemic absorption and allowing for chronic treatment Isotretinoin is widely viewed as the most effective therapy for several skin conditions, including ichthyosis, but it is only available orally, where high dose, chronic
Slide 13: TMB-001 Clinical Trial Results
TMB-001Clinical Trial Results Phase Ib/IIa study of TMB-001 in Congenital Ichthyosis TMB-001 (0.1%) Percent of Subject Achieving 2-point reduction on Day 57 Vehicle 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 1 Baseline 2 Day 57 TMB-001 (0.1%) TMB-001 (0.1%) IGA Scaling Active 0.1% Vehicle 3 Day 84 14 NY
Slide 14: TMB-001 Commercial Opportunity
TMB-001Topical Isotretinoin in CI Commercial Opportunity • • Dermatologists already familiar with oral Accutane® / Isotretinoin Payor landscape based on key findings from reimbursement analysis: • Formulary access will be swift and a formality due to orphan status and TMB-001 positioned as only FDA
Slide 15: TMB-001 Phase 2B Study Design (CONTROL Study)
TMB-001 Phase 2B Study Design (CONTROL Study) Treatment of Congenital Ichthyosis decrease in VIIS scaling score • PRO (itch, DLQI) • Multi-center global trial (US and Australia) 16 NYSE American: TMBR Title A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Primary Obj
Slide 16: TMB-002 Topical Rapamycin Leading the Competition
TMB-002Topical Rapamycin Leading the Competition (Pascomer®) Compounded topical rapamycin is disadvantageous for many reasons • • • Not approved by regulators May provides inconsistent quality, homogeneity and potency Expensive and unreimbursed for patients (>$30K-$50K per annual course of therapy f
Slide 17: TMB-002 for Facial Angiofibromas in Tuberous Sclerosis
TMB-002 for Facial Angiofibromas in Tuberous Sclerosis TSC is a multisystem genetic disorder affecting approximately 50,000 people in the US TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth of hamartomas in multiple organs Preva
Slide 18: TMB-002 Topical Rapamycin (Pascomer)
TMB-002Topical Rapamycin (Pascomer®) Potentially the First Commercially Available, High-Quality Topical Formulation of Rapamycin with Broad Access Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) Development Stage • Efficacy of topical rapamycin demonstrated in multiple well contr
Slide 19: TMB-002 Commercial Opportunity
TMB-002Topical Rapamycin (Pascomer®) Commercial Opportunity Dermatologists already familiar with rapamycin and its potential in TSC • Defined target group (64 U.S. specialist clinics) can be reached with a small salesforce Payor landscape based on key findings from reimbursement analysis: • All payo
Slide 20: TMB-002 (Pascomer) Phase 2B Study Design
TMB-002 (Pascomer®) Phase 2B Study Design Tuberous Sclerosis Complex two grades from baseline • Percentage improvement in FA, as assessed by the participant or parent/caregiver • Efficacy and Safety of Two Concentrations of TMB-002 21 NYSE American: TMBR Title Dose-Ranging Efficacy and Safety Study
Slide 21: TMB-003 Locally Delivered Highly Selective ET-A Inhibitor
TMB-003Locally Delivered Highly Selective ET-A inhibitor Sitaxsentan Sitaxsentan was a highly selective (6,500:1) ET-A receptor antagonist previously on the market in the EU, Canada and Australia as an oral treatment for PAH, but voluntarily withdrawn from global market in 2010 due to risks of liver
Slide 22: Localized Scleroderma
Localized Scleroderma Rare connective tissue disorder affecting approximately 90,000 people in the US Localized Scleroderma is a rare, autoimmune connective tissue disorder (CTD) characterized by inflammation and thickening of the skin from excessive collagen deposition. It is more common in childre
Slide 23: Anticipated Near Term Milestones
Anticipated Near Term Milestones 24 NYSE American: TMBR TMB-001 TMB-002 TMD-003 Q3 2020 Phase 2B – Opening of all sites Phase 2B – Opening of all sites Reach 50% enrollment Q4 2020 Reach 50% enrollment Formulation milestone Publish data from Phase 2A study Q1 2021 Complete enrollment Complete enroll
Slide 24: Financial and Capitalization Highlights
25 Financial and Capitalization Highlights As a result of the merger, Timber Pharmaceuticals LLC became a wholly owned subsidiary of BioPharmX Corporation, which changed its name to Timber Pharmaceuticals, Inc. Upon closing of the merger, Timber received $20 million of funding from certain instituti
Slide 25: Topical Isotretinoin for Congenital Ichthyosis Topical Rapamycin for Facial Angiofibromas in Tuberous Sclerosis Complex
26 Topical Isotretinoin for Congenital Ichthyosis Topical Rapamycin for Facial Angiofibromas in Tuberous Sclerosis Complex Locally Delivered Endothelin-A Antagonist for Localized Scleroderma Recently acquired Topical Minocycline programs Label expansion opportunities for all programs Track record of
Slide 26: Building Bridges in Medical Dermatology - Thank You
Building Bridges in Medical Dermatology Thank You For additional Investor Information please contact: John Koconis CEO [email protected] Stephanie Prince PCG Advisory [email protected] (646) 762-4518 www.timberpharma.com
Slide 27: Timber Pharmaceuticals - Thank You
E TIMBER PHARMACEUTICALS Building Bridges in Medical Dermatology Thank You For additional Investor Information please contact: John Koconis Stephanie Prince CEO PCG Advisory [email protected] [email protected] (646) 762-4518 www.timberpharma.com
Timber Pharmaceuticals — Investor Presentation (May 2020) on 6ix